SynthesisOncotarget2017

Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials.

Yandun Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.